Gammalinolenic acid treatment of fatigue associated with primary Sjögren's syndrome.

• Objective: To evaluate the eYcacy of the essential omega-6 fatty acid Gammalinolenic acid (GLA) on fatigue associated with primary Sjo¨ gren’s syndrome. Methods: Ninety patients with primary Sjo¨ gren’s syndrome (with or without signs of autoimmunity) entered a 6-month double blind placebo-controlled randomised trial with high dose GLA (extracted from Evening Primrose Oil ) or corn oil. The primary outcome parameter was fatigue; secondary endpoints were eye dryness, mouth dryness, muscle and joint pain. Results: No statistically signiŽ cant improvement was found in fatigue assessed by Visual Analogue Scale (VAS) or in the time needed for sleeping/resting during a 24-hour period. No diVerences were found between the treatment and placebo group. The same applies to the secondary endpoints: no diVerences in VAS for eye and mouth dryness or pain, no signiŽ cant changes in Schirmer-1-test, van Bijsterveld score, unstimulated whole sialometry (UWS), or use of artiŽ cial tears or analgesics. Only mild side eVects were observed. Conclusion: According to our study results GLA (Evening Primrose oil ) treatment for fatigue in primary Sjo¨gren’s syndrome is ineVective.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)

Nyckelord

Non-U.S. Gov't

Treatment Outcome

gamma-Linolenic Acid: administration & dosage

Fatigue: etiology

Fatty Acids

Aged

Dermatologic Agents

Double-Blind Method

Fatigue: drug therapy

gamma-Linolenic Acid: adverse effects

Essential

Female

Human

Male

Middle Age

Patient Compliance

Sjogren's Syndrome: complications

Sjogren's Syndrome: drug therapy

Support

Publikations- och innehållstyp

art (ämneskategori)

ref (ämneskategori)